You are here: Home » Companies » News
Business Standard

Strong demand for cancer drugs drives AstraZeneca to sales growth in Q3CY18

It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which staved off a takeover bid from Pfizer four years ago, rose 2% by 0920 GMT on Thursday

Ben Hirschler | Reuters  |  London 

Strong demand for AstraZeneca's new drugs -- especially those for cancer -- drove a return to sales growth in the third quarter and the drugmaker said it now anticipated years of sustained improvement. Product sales in the three months rose 8 per cent, or 9 per cent in constant currencies, which is the benchmark AstraZeneca uses for measuring the return to growth that it has been promising for 2018. It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which staved off a takeover bid from Pfizer four years ago, rose 2 per cent by 0920 ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, November 08 2018. 15:16 IST
RECOMMENDED FOR YOU